Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically or cytologically confirmed adenocarcinoma of the prostate that is castration-resistant, defined as:~  * A castrate serum testosterone level =\< 50 ng/dL or 1.7 nmol/L~ * Bilateral orchiectomy or maintenance on androgen ablation therapy with luteinizing hormone-releasing hormone (LHRH). Androgen deprivation therapy needs to be maintained throughout the study unless a patient has had orchiectomy by surgery~ * Serum PSA progression defined as two consecutive increases in PSA over a previous reference value, each measurement at least 1 week apart~* Progression after androgen receptor blockers (enzalutamide, apalutamide, or darolutamide) or androgen synthesis blockers (abiraterone acetate) or chemotherapy (docetaxel or cabazitaxel). There are no maximum number of prior therapies~* Progressive castration-resistant prostate cancer with two or more skeletal metastases identified by Tc-99m bone scintigraphy or prostate specific membrane antigen (PSMA) positron emission tomography (PET) scan~* Patients must have self-reported moderate to severe pain at trial entry (baseline weekly average worst pain in the past 24-hours scores of \>= 4 on an 11-point numeric rating scale \[NRS\], the Brief Pain Inventory - Short Form \[BPI-SF\] item #3 for worst pain)~* Patients must either currently employ regular (not occasional) analgesic medication use for cancer-related bone pain or have undergone treatment with external beam radiation therapy (EBRT) for bone pain within 4 weeks before starting study treatment~* Age \>= 18 years. Children \< 18 years of age are excluded from the study as the prevalence of prostate cancer is extremely rare in this age group~* Patients must have a life expectancy \>= 3 months~* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 60%)~* Patients must have a serum PSA value \>= 1 ng/mL~* Absolute neutrophil count \>= 1,000/mcL~* Platelets \>= 100,000/mcL~* Hemoglobin \> 10.0 g/dL~* Total bilirubin =\< 2.5 x institutional upper limit of normal (ULN)~* Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase \[SGPT\]) =\< 5 x institutional ULN~* Creatinine =\< 1.7 mg/dL OR glomerular filtration rate (GFR) \>= 50 mL/min/1.73 m\^2~* Patients receiving bisphosphonates prior to enrollment can maintain bisphosphonate therapy throughout all or part of the study. The bisphosphonate may be stopped or started at the discretion of the investigator throughout the study (i.e., both treatment phase and follow-up). Injection of bisphosphonates should be done at least 2 hours before or after study drug administration~* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial~* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated~* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load~* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial~* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification. To be eligible for this trial, patients should be class 2B or better~* The effects of Sn-117m-DTPA on the developing human fetus are unknown. For this reason and because radionuclides are known to be teratogenic, male participants and their female partners must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while her male partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of Sn-117m-DTPA administration~* Patients must be willing and able to comply with the protocol and agree to return to the hospital for follow-up visits and examinations~* Ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~* Patients must not have visceral metastases (such as liver and lung) as assessed by abdominal/pelvic computed tomography (CT) or chest X-ray within 12 weeks before starting study treatment~* Patients must not have malignant lymphadenopathy exceeding 3 cm in short-axis diameter~* Patients must not have imminent or established spinal cord compression based on clinical findings and/or magnetic resonance imaging (MRI)~* Patients who have had chemotherapy, immunotherapy, or external radiotherapy within 4 weeks prior to entering the study~* Patients must not have received systemic radiotherapy with radium-223, strontium-89, samarium-153, rhenium-186, or rhenium-188 for the treatment of bony metastases within 24 weeks before starting study treatment~* Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> grade 1) with the exception of alopecia~* Patients must not have received any investigational agents within 4 weeks before starting study treatment, nor be scheduled to receive one during the planned treatment period~* Patients must not have unmanageable urinary incontinence~* Patients must not have had known non-pathological bone fractures within 2 months before starting study treatment~* Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to Sn-117m-DTPA~* Patients must not have uncontrolled intercurrent illness, including:~  * Any uncontrolled infection~ * Grade 2 or greater motor or sensory neuropathy~ * Crohn's disease or ulcerative colitis~* Patients with psychiatric illness/social situations that would limit compliance with study requirements

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tin Sn 117m DTPA (Type: EXPERIMENTAL): Patients receive tin Sn 117m DTPA IV over 5-10 minutes on day 1. Treatment repeats every 8 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive tin Sn 117m DTPA for an additional 2 cycles if pain recurs within 6 months after a 16-week pain observation period and no disease progression on bone scans, or evidence of clinical progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).